Scientific Library
Proteasome inhibitor approved by FDA for Myeloma retreatment
The U.S. Food and Drug Administration (FDA) has approved Velcade (Bortezomib) for the retreatment of adult patients with Multiple Myeloma who had previously responded to Velcade therapy and relapsed at
Immunotherapy for breast cancer: Types and effectiveness
Our body is made up of trillions of cells grouped together to form tissues and organs. The genes present in the nucleus of every cell tell it when to grow, work, divide and die.
Normally, our cells